5 completed, 2 active not recruiting, 2 terminated. 6 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Recurrent Lip and Oral Cavity Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Lip and Oral Cavity Squamous Cell Carcinoma trials Research Report on Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-10-01 |
| Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Communication Intervention, Watch video, Module completion of the Prepare to Care kit - Caregiver, Malignant Head and Neck Neoplasm | Not applicable | Completed | Wake Forest University Health Sciences | 35 | 2017-05-15 | 2023-01-09 |
| Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium - Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 3 | 2014-04-01 | 2017-10-11 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Cetuximab, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2011-02-10 | 2020-03-13 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
| Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2016-10-24 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Bevacizumab, Carboplatin, Cisplatin - Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 403 | 2008-08-08 | 2026-10-22 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Cediranib Maleate, Laboratory Biomarker Analysis - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2007-02-01 | 2015-05-05 |
Lymphoid Interstitial Pneumonia (9) · Squamous Cell Carcinoma of Head and Neck (9) · Tongue Neoplasms (7) · Salivary Gland Neoplasms (4) · Carcinoma (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Mouth Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Oropharyngeal Neoplasms (1) · Rectal Neoplasms (1)
Carcinoma, Squamous Cell (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Carcinoma (8) · Head and Neck Neoplasms (8) · Mouth Diseases (8) · Stomatognathic Diseases (8) · Mouth Neoplasms (7) · Tongue Diseases (7) · Salivary Gland Diseases (4) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1)
1,2-diaminocyclohexaneplatinum II citrate (3) · Cetuximab (3) · Cisplatin (3) · Platinum (3) · Bevacizumab (2) · Carboplatin (2) · Disulfides (2) · Docetaxel (2) · Immunoglobulin G (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1-phenyl-3,3-dimethyltriazene (1) · Dihematoporphyrin Ether (1) · Educational Status (1) · Fluorouracil (1) · Lenalidomide (1)
National Cancer Institute (NCI) (7) · Roswell Park Cancer Institute (1) · Wake Forest University Health Sciences (1)
United States (8) · Canada (1) · China (1) · Puerto Rico (1) · South Africa (1)
Aarti Bhatia (1) · Chandylen Nightingale (1) · Eric Winquist (1) · Erin M Bertino (1) · Greg Wolf (1) · Hassan Arshad (1) · James Rocco (1) · Tanguy Seiwert (1)
U10CA180820 (2), N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA012197 (1), P30CA014599 (1), P30CA016056 (1), P30CA016058 (1), P30CA046592 (1), R03CA208560 (1), R21CA119591 (1), U01CA076576 (1), U10CA021115 (1)